Working the endless puzzle of hereditary autoinflammatory disorders

Modern Rheumatology

Volumn 24, Issue 3, 2014, Pages 381-389

  Caso, Francesco ^a   Cantarini, Luca ^b   Lucherini, Orso Maria ^b   Sfriso, Paolo ^a   Fioretti, Maria ^c   Costa, Luisa ^a   Vitale, Antonio ^b   Atteno, Mariangela ^d   Galeazzi, Mauro ^b   Muscari, Isabella ^b   Magnotti, Flora ^b   Frediani, Bruno ^b   Punzi, Leonardo ^a   Rigante, Donato ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Amyloidosis; Hereditary autoinflammatory disorders; Inflammation; Interleukin 1 ; Recurrent fever

Indexed keywords

INFLAMMASOME; INTERLEUKIN 1BETA; CYTOKINE;

AUTOINFLAMMATORY DISEASE; CINCA SYNDROME; CYTOKINE RELEASE; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENETIC ANALYSIS; GENETIC DISORDER; GRANULOMATOSIS; HEREDITARY PERIODIC FEVER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INNATE IMMUNITY; LABORATORY TEST; PAPA SYNDROME; PRIORITY JOURNAL; REVIEW; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; GENETICS; METABOLISM;

CYTOKINES; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1BETA;

EID: 84900425714     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.843755     Document Type: Review

References (96)

1. Rigante D. T he fresco of autoinfl ammatory diseases from the pediatric perspective. Autoimmun Rev. 2012; 11: 348-56
2. Lamkanfi M. Dixit VM. Infl ammasomes: Guardians of cytosolic sanctity. Immunol Rev. 2009; 227: 95-105
3. Kanazawa N. Rare hereditary autoinfl ammatory disorders: Towards an understanding of critical in vivo infl ammatory pathways. J. Dermatol Sci. 2012; 66: 183-9
4. Touitou I. Kone -Paut I. Autoinfl ammatory diseases. Best Pract Res Clin Rheumatol. 2008; 22: 811-29
5. Cantarini L. Rigante D. Brizi MG. Lucherini OM. Sebastiani GD Vitale A. et al. Clinical and biochemical landmarks in systemic autoinfl ammatory diseases. Ann Med. 2012; 44: 664-73
6. Masters SL. Simon A. Aksentijevich I. Kastner DL. Horror autoinfl ammaticus: The molecular pathophysiology of autoinfl ammatory disease. Annu Rev Immunol. 2009; 27: 621-68
7. Muscari I. Iacoponi F. Cantarini L. Lucherini OM. Simonini G Brizi MG. et al. The diagnostic evaluation of patients with potential adult-onset autoinfl ammatory disorders: Our experience and review of the literature. Autoimmun Rev. 2012; 12: 10-3
8. Cantarini L. Lucherini OM. Iacoponi F. Cimaz R. Simonini G Rigante D. et al. Development and preliminary validation of a diagnostic score for identifying patients aff ected with adult-onset autoinfl ammatory disorders. Int J Immunopathol Pharmacol. 2010; 23: 1133-41
9. Cantarini L. Iacoponi F. Lucherini OM. Obici L. Brizi MG. Cimaz R. et al. Validation of a diagnostic score for the diagnosis of autoinfl ammatory diseases in adults. Int J Immunopathol Pharmacol. 2011; 24: 695-702
10. Soriano A. Manna R. Familial Mediterranean fever: New phenotypes. Autoimmun Rev. 2012; 12: 31-7
11. Centola M. Wood G. Frucht D M Galon J. Aringer M. Farrell C. e t a l. The gene for familial Mediterranean fever MEFV is expressed in early leukocyte development and is regulated in response to infl ammatory mediators. Blood. 2000; 95: 3223-31
12. Chae J J Wood G. Richard K. Jaffe H. Colburn NT. Masters SL et al. The familial Mediterranean fever protein pyrin is cleaved by caspase-1 and activates NF-kappaB through its N-Terminal fragment. Blood. 2008; 112: 1794-803
13. B en-Chetrit E. Touitou I. T he impact of MEFV gene identifi cation on FMF: N appraisal after 15 years. Clin Exp Rheumatol. 2012; 30 (3 Suppl 72): S3-6
14. McDermott MF. Aksentijevich I. The autoinfl ammatory syndromes. Curr Opin Allergy Clin Immunol. 2002; 2: 511-6
15. Savic S. Dickie LJ. Battellino M. McDermott MF. Familial Mediterranean fever and related periodic fever syndromes/autoinfl ammatory diseases. Curr Opin Rheumatol. 2012; 24: 103-12
16. Akkoc N. Gul A. Familial Mediterranean fever and seronegative arthritis. Curr Rheumatol Rep. 2011; 13: 388-94
17. Radakovic S. Holzer G. Tanew A. Erysipelas-like erythema as a cutaneous sign of familial Mediterranean fever: Case report and review of the histopathologic fi ndings. J. Am Acad Dermatol. 2013; 68: E61-3
18. Aksu K. Keser G. Coexistence of vasculitides with familial Mediterranean fever. Rheumatol Int. 2011; 31: 1263-74
19. Karachaliou I. Karachalios G. Charalabopoulos A. Charalabopoulos K. Meningitis associated with familial Mediterranean fever. Int J Clin Pract Suppl. 2005; 147: 60-1
20. Senel K. Melikoglu M A Baykal T. Melikoglu M. Erdal A. Ugur M. Protracted febrile myalgia syndrome in familial Mediterranean fever. Mod Rheumatol. 2010; 20: 410-2
21. Medlej-Hashim M. Loiselet J. Lefranc G. M e g arbane A. Familial Mediterranean Fever (FMF): From diagnosis to treatment. Sante. 2004; 14: 261-6
22. Rigante D. Capoluongo E. The plodding diagnosis of monogenic autoinfl ammatory diseases in childhood: From the clinical scenery to laboratory investigation. Clin Chem Lab Med. 2011; 49: 783-91
23. Altuno g lu A. Erten S. Canoz MB. Yuksel A. Ceylan GG. Balci S et al. Phenotype 2 familial Mediterranean fever: Evaluation of 22 case series and review of the literature on phenotype 2 FMF. Ren Fail. 2013; 35: 226-30
24. Livneh A. Langevitz P. Zemer D. Zaks N. Kees S. Lidar T. et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997; 40: 1879-85
25. Kon e -Paut I. Hentgen V. Guillaume-Czitrom S. Compeyrot-Lacassagne S Tran TA. Touitou I. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology (Oxford). 2009; 48: 840-2
26. Rigante D. L a Torraca I. Ansuini V. Compagnone A. Salli A Stabile A. The multi-face expression of familial Mediterranean fever in the child. Eur Rev Med Pharmacol Sci. 2006; 10: 163-71
27. Rigante D. La Torraca I. Avallone L. Pugliese AL. Gaspari S Stabile A. The pharmacological basis of treatment with colchicine in children with familial Mediterranean fever. Eur Rev Med Pharmacol Sci. 2006; 10: 173-8
28. Taskiran E Z Cetinkaya A. Balci-Peynircioglu B. Akkaya Y Z Yilmaz E. The eff ect of colchicine on pyrin and pyrin interacting proteins. J. Cell Biochem. 2012; 113: 3536-46
29. Ozturk MA. Kanbay M. Kasapoglu B. Onat AM. Guz G. Furst DE et al. Therapeutic approach to familial Mediterranean fever: Review update. Clin Exp Rheumatol. 2011; 29(4 Suppl 67): S77-86
30. Cantarini L. Lucherini OM. Muscari I. Frediani B. Galeazzi M Brizi MG et al. Tumour necrosis factor receptor-Associated periodic syndrome (TRAPS): State of the art and future perspectives. Autoimmun Rev. 2012; 12: 38-43
31. Chan FK. Chun HJ. Zheng L. Siegel RM. Bui KL. Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000; 288: 2351-4
32. McDermott MF. Aksentijevich I. Galon J. McDermott EM. Ogunkolade BW. Centola M et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor TNFR1 defi ne a family of dominantly inherited autoinfl ammatory syndromes. Cell. 1999; 97: 133-44
33. Aksentijevich I. Galon J. Soares M. Mansfi eld E. Hull K. Oh HH. et al. The tumor-necrosis factor receptor-Associated periodic syndrome: New mutations in TNFRSF1A ancestral origins genotype-phenotype studies and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet. 2001; 69: 301-14
34. Ravet N. Rouaghe S. Dode C. Bienvenu J. Stirnemann J. L e v y P. e t a l. Clinical signifi cance of P46L and R92Q substitutions in the tumor necrosis factor superfamily 1A gene. Ann Rheum Dis. 2006; 65 : 1158-62
35. Turner M D Chaudhry A. Nedjai B. Tumour necrosis factor receptor traffi cking dysfunction opens the TRAPS door to pro-infl ammatory cytokine secretion. Biosci Rep. 2012; 32: 105-12
36. Dod e C. Andr e M. Bienvenu T. Hausfater P. P e cheux C Bienvenu J et al; French Hereditary Recurrent Infl ammatory Disorder Study Group. The enlarging clinical genetic and population spectrum of tumor necrosis factor receptor-Associated periodic syndrome. Arthritis Rheum. 2002; 46: 2181-8
37. Rigante D. Cantarini L. Imazio M. Lucherini OM. Sacco E Galeazzi M et al. Autoinfl ammatory diseases and cardiovascular manifestations. Ann Med. 2011; 43: 341-6
38. Hull KM. Wong K. Wood GM. Chu WS. Kastner DL. Monocytic fasciitis: Newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum. 2002; 46: 2189-94
39. Cantarini L. Lucherini OM. Baldari CT. Laghi Pasini F Galeazzi M. Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-Associated periodic syndrome. Clin Exp Rheumatol. 2010; 28: 405-7
40. Cantarini L. Lucherini O M Brucato A. Barone L. Cumetti D Iacoponi F. et al. Clues to detect tumor necrosis factor receptorassociated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: Results of a multicentre study. Clin Res Cardiol. 2012; 101: 525-31
41. Rigante D. The protean visage of systemic autoinfl ammatory syndromes: Challenge for inter-professional collaboration. Eur Rev Med Pharmacol Sci. 2010; 14: 1-18
42. Stankovic K. Grateau G. Auto infl ammatory syndromes: Diagnosis and treatment. Joint Bone Spine. 2007; 74: 544-50
43. Federici L. Rittore-Domingo C. Kone -Paut I. Jorgensen C. Rodie r e M Le Quellec A. et al. Adecision tree for genetic diagnosis of hereditary periodic fever in unselected patients. Ann Rheum Dis. 2006; 65 : 1427-32
44. Sinož i c D. Toplak N. Milotic I. Tumor necrosis factor receptorassociated periodic fever syndrome in a 58-year-old man: Caution not to discount TRAPS as a diagnosis in older patients. J. Clin Rheumatol. 2011; 17: 325-8
45. Bulua AC. Mogul DB. Aksentijevich I. Singh H. He DY. Muenz LR et al. Effi cacy of etanercept in the tumor necrosis factor receptorassociated periodic syndrome: Prospective open-label doseescalation study. Arthritis Rheum. 2012; 64: 908-13
46. Scallon B. Cai A. Solowski N. Rosenberg A. Song X Y Shealy D. e t a l. Binding and functional comparison of two types of tumor necrosis factor antagonists. J. Pharmacol Exp Ther. 2002; 301: 418-26
47. Cantarini L. Rigante D. Lucherini O M Cimaz R. Laghi Pasini F Baldari CT. et al. Role of etanercept in the treatment of tumor necrosis factor receptor-Associated periodic syndrome: Personal experience and review of the literature. Int J Immunopathol Pharmacol. 2010; 23: 701-7
48. Gattorno M. Pelagatti M A Meini A. Obici L. Barcellona R Federici S. et al. Persistent effi cacy of anakinra in patients with tumor necrosis factor receptor-Associated periodic syndrome. Arthritis Rheum. 2008; 58: 1516-20
49. Obici L. Meini A. Cattalini M. Chicca S. Galliani M. Donadei S. e t a l. Favourable and sustained response to anakinra in tumour necrosis factor receptor-Associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis. 2011; 70: 1511-2
50. Brizi MG. Galeazzi M. Lucherini OM. Cantarini L. Cimaz R. Successful treatment of tumor necrosis factor receptor-Associated periodic syndrome with canakinumab. Ann Intern Med. 2012; 156: 907-8
51. Vaitla P M Radford P M Tighe P J Powell R J McDermott E M Todd I. et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-Associated periodic syndrome: Ssessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum. 2011; 63: 1151-5
52. Houten SM. Wanders RJ. Waterham HR. Biochemical and genetic aspects of mevalonate kinase and its defi ciency. Biochim Biophys Acta. 2000; 1529: 19-32
53. Haas D. Hoff mann GF. Mevalonate kinase defi ciencies: From mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis. 2006; 1: 13
54. Frenkel J. Rijkers G T Mandey S H Buurman S W Houten S M Wanders RJ. et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 2002; 46: 2794-803
55. Prasad C. Salvadori M I Rupar C A. Severe phenotypic spectrum of mevalonate kinase defi ciency with minimal mevalonic aciduria. Mol Genet Metab. 2012; 107: 756-9
56. Toplak N. Dolezalova P. Constantin T. Sediva A. Paš i c S. Ciž n ar P et al; Eastern/Central European autoinfl ammatory collaborating group for the Paediatric Rheumatology International Trials Organization (PRINTO) and Eurofever Project. Periodic fever syndromes in Eastern and Central European countries: Results of a pediatric multinational survey. Pediatr Rheumatol Online J. 2010; 8: 29
57. v an Der Hilst J C Bodar E J Barron K S Frenkel J. Drenth J P van Der Meer JW. et al; International HIDS Study Group. Long-Term follow-up clinical features and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore). 2008; 87: 301-10
58. Simon A. Kremer H P Wevers R A Scheff er H. De Jong JG Van Der Meer JW. et al. Mevalonate kinase defi ciency: Evidence for a phenotypic continuum. Neurology. 2004; 62: 994-7
59. Obici L. Manno C. Muda A O Picco P. D O sualdo A. Palladini G et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum. 2004; 50: 2966-9
60. Sornsakrin M. Wenner K. Ganschow R. Bcell cytopenia in two brothers with hyper-IgD and periodic fever syndrome. Eur J Pediatr. 2009; 168: 825-31
61. Tahara M. Sakai H. Nishikomori R. Yasumi T. Heike T. Nagata I et al. Patient with neonatal-onset chronic hepatitis presenting with mevalonate kinase defi ciency with a novel MVK gene mutation. Mod Rheumatol. 2011; 21: 641-5
62. Breda L. Nozzi M. D i Marzio D. D e Sanctis S. Gattorno M. Chiarelli F. Recurrent pericarditis in hyper-IgD syndrome. Clin Exp Rheumatol. 2009; 27: 695
63. Bader-Meunier B. Florkin B. Sibilia J. Acquaviva C. Hachulla E Grateau G. et al; SOFREMIP. CRI. Mevalonate kinase defi ciency: Survey of 50 patients. Pediatrics. 2011; 128: E152-9
64. v an Der Hilst J C Frenkel J. Hyperimmunoglobulin D syndrome in childhood. Curr Rheumatol Rep. 2010; 12: 101-7
65. Simon A. Drewe E. van Der Meer J W Powell R J Kelley R I Stalenhoef AF. et al. Simvastatin treatment for infl ammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther. 2004; 75: 476-83
66. Topalog l u R. Ayaz N A Waterham H R Y u c e A. Gumruk F. Sanal O. Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up. Clin Rheumatol. 2008; 27: 1317-20
67. Galeotti C. Meinzer U. Quartier P. Rossi-Semerano L. Bader-Meunier B. Pillet P. et al. Effi cacy of interleukin-1-Targeting drugs in mevalonate kinase defi ciency. Rheumatology (Oxford). 2012; 51: 1855-9
68. Cantarini L. Lucherini O M Frediani B. Brizi M G Bartolomei B Cimaz R. et al. Bridging the gap between the clinician and the patient with cryopyrin-Associated periodic syndromes. Int J Immunopathol Pharmacol. 2011; 24: 827-36
69. Miyamae T. Cryopyrin-Associated periodic syndromes: Diagnosis and management. Paediatr Drugs. 2012; 14: 109-17
70. Lepore L. Paloni G. Caorsi R. Alessio M. Rigante D. Ruperto N. e t a l. Follow-up and quality of life of patients with cryopyrin-Associated periodic syndromes treated with Anakinra. J. Pediatr. 2010; 157 : 310-5
71. Kubota T. Koike R. Cryopyrin-Associated periodic syndromes:Background and therapeutics. Mod Rheumatol. 2010; 20: 213-21
72. Yu JR. Leslie KS. Cryopyrin-Associated periodic syndrome: N update on Diagnosis and treatment response. Curr Allergy Asthma Rep. 2011; 11: 12-20
73. Stych B. Dobrovolny D. Familial cold auto-infl ammatory syndrome (FCAS): Characterization of symptomatology and impact on patients lives. Curr Med Res Opin. 2008; 24: 1577-82
74. Hawkins PN. Lachmann HJ. Aganna E. McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004; 50: 607-12
75. Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep. 2011; 13: 123-31
76. Rigante D. Ansuini V. Caldarelli M. Bertoni B. L a Torraca I Stabile A. Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv Syst. 2006; 22: 334-7
77. Neven B. Marvillet I. Terrada C. Ferster A. Boddaert N. Couloignier V. et al. Long-Term effi cacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem infl ammatory disease/chronic infantile neurologic cutaneous articular syndrome. Arthritis Rheum. 2010; 62: 258-67
78. Tanaka N. Izawa K. Saito M K Sakuma M. Oshima K. Ohara O et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic cutaneous articular syndrome: Results of an International Multicenter Collaborative Study. Arthritis Rheum. 2011; 63: 3625-32
79. Lachmann HJ. Kone-Paut I. Kuemmerle-Deschner JB Leslie KS. Hachulla E. Quartier P. et al. Use of canakinumab in the cryopyrinassociated periodic syndrome. NEngl J Med. 2009; 360: 2416-25
80. J e ru I. Le Borgne G. Cochet E. Hayrapetyan H. Duquesnoy P Grateau G et al. Identifi cation and functional consequences of a recurrent NLRP12 missense mutation in periodic fever syndromes. Arthritis Rheum. 2011; 63: 1459-64
81. Sfriso P. Caso F. Tognon S. Galozzi P. Gava A. Punzi L. Blau syndrome clinical and genetic aspects. Autoimmun Rev. 2012; 12: 44-51
82. Rose C D Martin T M Wouters C H. Blau syndrome revisited. Curr Opin Rheumatol. 2011; 23: 411-8
83. Chen G. Shaw M H Kim Y G Nun e z G. N OD-like receptors: Role in innate immunity and infl ammatory disease. Annu Rev Pathol. 2009; 4: 365-98
84. Villanueva-Mendoza C. Arellanes-Garci a L. Cubas-Lorenzo V Jimenez-Martinez MC Flores-Suarez LF. Zenteno JC. Familial case of Blau syndrome associated with a CARD15/NOD2 mutation. Ophthalmic Genet. 2010; 31: 155-8
85. Borzutzky A. Fried A. Chou J. Bonilla F A Kim S. Dedeoglu F. N OD2-Associated diseases:Bridging innate immunity and autoinfl ammation. Clin Immunol. 2010; 134: 251-61
86. Punzi L. Furlan A. Podswiadek M. Gava A. Valente M De Marchi M. et al. Clinical and genetic aspects of Blau syndrome: 25-year follow-up of one family and a literature review. Autoimmun Rev. 2009; 8: 228-32
87. Yasui K. Yashiro M. Tsuge M. Manki A. Takemoto K Yamamoto M et al. Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: Its possible action and mechanism. Arthritis Rheum. 2010; 62: 250-7
88. Heiligenhaus A. Wefelmeyer D. Wefelmeyer E. R o s el M Schrenk M. The eye as a common site for the early clinical manifestation of sarcoidosis. Ophthalmic Res. 2011; 46: 9-12
89. Tallon B. Corkill M. Peculiarities of PAPA syndrome. Rheumatology (Oxford). 2006; 45: 1140-3
90. Smith EJ. Allantaz F. Bennett L. Zhang D. Gao X. Wood G. et al. Clinical Molecular and Genetic Characteristics of PAPA Syndrome: Review. Curr Genomics. 2010; 11: 519-27
91. Schellevis M A Stoff els M. Hoppenreijs E P Bodar E. Simon A van Der Meer JW. Variable expression and treatment of PAPA syndrome. Ann Rheum Dis. 2011; 70: 1168-70
92. Aksentijevich I. Masters SL. Ferguson PJ. Dancey P. Frenkel J van Royen-Kerkhoff A et al. An autoinfl ammatory disease with defi ciency of the interleukin-1-receptor antagonist. NEngl J Med. 2009; 360: 2426-37
93. Ferguson P J Chen S. Tayeh M K Ochoa L. Leal S M Pelet A. e t a l. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J. Med Genet. 2005; 42: 551-7
94. Obici L. Merlini G. Amyloidosis in autoinfl ammatory syndromes. Autoimmun Rev. 2012; 12: 14-7
95. Obici L. Merlini G. AA amyloidosis:Basic knowledge unmet needs and future treatments. Swiss Med Wkly. 2012; 142: W13580
96. van Der Hilst JC. Recent insights into the pathogenesis of type AA amyloidosis. Sci World J. 2011; 11: 641-50